Ildong Pharmaceutical said on the 11th that its operating profit on a consolidation basis last year was 19.5 billion won, up 48.5% from a year earlier, according to preliminary figures.
Sales during the same period fell 7.8% to 566.9 billion won, and net profit came to 23.7 billion won.
The company cited fixed expense reductions and expense structure efficiency from business realignment as the backdrop for the improved profitability. It noted that operating profit increased sharply as it streamlined the overall expenditure structure.
However, it said the decline in sales was affected by a base effect from the co-promotion (joint sales) contract with Bayer Korea that ended in late 2024.
Meanwhile, Ildong Pharmaceutical will pay cash dividends as part of shareholder returns following improved earnings. It will pay 200 won per common share, with total dividends of 6.3 billion won. The record date is Mar. 31, and the dividends are scheduled to be paid within one month after approval at the regular shareholders meeting.